-0.000496106317087166 -0.00132295017889894 -0.000766709762771136 -0.00276616855587966 -0.000616374515168949 -0.0126431943233412 -0.0119215851348508 -0.0250458522505188
Thanks for submitting the form.
Stockreport

Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout [Yahoo! Finance]

General Electric Company (GE)  More Company Research Source: Yahoo! Finance
Last general electric company earnings: 4/30 04:02 pm Check Earnings Report
US:NYSE Investor Relations: ge.com/investor-relations/overview
Ryan McMillian named Head of Financial Strategy to support corporate strategy and long-term growth MISSOULA, Mont. March 5, 2026 /PRNewswire/ -- Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Ferdinand Massari, M.D., as Chief Medical Officer (CMO), and Ryan McMillian as Head of Financial Strategy. The appointments strengthen the leadership team as Inimmune advances its lead allergic rhinitis program, INI-2004, toward key milestones and planned expansion into allergic asthma and food allergy. Inimmune "Inimmune is entering an important phase of growth as we continue to advance our pipeline and broaden our capabilities," said David Burkhart, Ph.D., Chief Executive Officer of Inimmune Corporation. "As we look ahead to upcoming clinical milestones, Dr. Massari's deep clinical development expertise and Mr. McMillian's financial leadership position us to execute with focus and discipline as [Read more]

IMPACT SNAPSHOT EVENT TIME: GE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GE alerts
from News Quantified
Stockreport

Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout [Yahoo! Finance]

General Electric Company  (GE) 
Last general electric company earnings: 4/30 04:02 pm Check Earnings Report
US:NYSE Investor Relations: ge.com/investor-relations/overview
Ryan McMillian named Head of Financial Strategy to support corporate strategy and long-term growth MISSOULA, Mont. March 5, 2026 /PRNewswire/ -- Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Ferdinand Massari, M.D., as Chief Medical Officer (CMO), and Ryan McMillian as Head of Financial Strategy. The appointments strengthen the leadership team as Inimmune advances its lead allergic rhinitis program, INI-2004, toward key milestones and planned expansion into allergic asthma and food allergy. Inimmune "Inimmune is entering an important phase of growth as we continue to advance our pipeline and broaden our capabilities," said David Burkhart, Ph.D., Chief Executive Officer of Inimmune Corporation. "As we look ahead to upcoming clinical milestones, Dr. Massari's deep clinical development expertise and Mr. McMillian's financial leadership position us to execute with focus and discipline as [Read more]

IMPACT SNAPSHOT
EVENT TIME:
GE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS